scholarly journals The non-benzodiazepine anxiolytic etifoxine limits the sensory-affective expression of pain following streptozotocin-induced diabetic neuropathy

2021 ◽  
Author(s):  
Géraldine Gazzo ◽  
Marlene Salgado Ferrer ◽  
Pierrick Poisbeau
Keyword(s):  
Neuroprotective Effect ◽  
Preventive Treatment ◽  
Allosteric Modulation ◽  
Receptor Function ◽  
Modulation Effect ◽  
Diabetic Type ◽  
Affective Expression ◽  
Chronic Hyperglycemia

AbstractMore than 450 million people worldwide suffer from diabetes, or 1 in 11 people. Chronic hyperglycemia degrades patients’ quality of life and the development of neuropathic pain contributes to the burden of this disease. In this study, we used the mouse model of streptozocin-induced diabetic type 1 neuropathy to assess the analgesic potential of etifoxine. Etifoxine is a prescribed anxiolytic that increases GABAAA receptor function through a direct positive allosteric modulation effect and, indirectly, by stimulating the production of endogenous GABAA receptor positive modulators such as allopregnanolone-type neurosteroids. We show that a curative or preventive treatment strongly and durably reduces mechanical hyperalgesia and anxiety in diabetic neuropathic mice. This analgesic and neuroprotective effect on painful symptoms and emotional comorbidities is promising and should now be clinically evaluated.

scholarly journals The non-benzodiazepine anxiolytic etifoxine limits mechanical allodynia and anxiety-like symptoms in a mouse model of streptozotocin-induced diabetic neuropathy

PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0248092
Author(s):  
Géraldine Gazzo ◽  
Marlene Salgado Ferrer ◽  
Pierrick Poisbeau
Keyword(s):  
Mouse Model ◽  
Mechanical Allodynia ◽  
Neuroprotective Effect ◽  
Preventive Treatment ◽  
Allosteric Modulation ◽  
Modulation Effect ◽  
Diabetic Type ◽  
Chronic Hyperglycemia

More than 450 million people worldwide suffer from diabetes, or 1 in 11 people. Chronic hyperglycemia degrades patients’ quality of life and the development of neuropathic pain contributes to the burden of this disease. In this study, we used the mouse model of streptozocin-induced diabetic type 1 neuropathy to assess the analgesic potential of etifoxine. Etifoxine is a prescribed anxiolytic that increases GABAAA receptor function through a direct positive allosteric modulation effect and, indirectly, by stimulating the production of endogenous GABAA receptor positive modulators such as allopregnanolone-type neurosteroids. We show that a post-symptomatic or preventive treatment strongly and durably reduces mechanical hyperalgesia and anxiety in diabetic neuropathic mice. This analgesic and neuroprotective effect on painful symptoms and emotional comorbidities is promising and should now be clinically evaluated.

scholarly journals Kinematic Analysis of the Musculoskeletal System Diabetic Type I

2018 ◽  
Vol 14 (15) ◽  
pp. 414
Author(s):  
Khaled Atiyat ◽  
Osama "Abdul Fattah" ◽  
Ayed Ali Zureigat
Keyword(s):  
Musculoskeletal System ◽  
Kinematic Analysis ◽  
Natural Extension ◽  
Video Camera ◽  
Type I ◽  
Diabetic Type ◽  
Type1 Diabetes ◽  
Study Results

This study aimed to apply the principles of biomechanics science correctly, also to be is nested in the treatment of diabetics, and establish kinematic record for musculoskeletal diabetics. In order to improve the quality of life and care for diabetics. To achieve this, the researchers used the kinematic analysis of the musculoskeletal system for (8) mail patients with type1 diabetes, purposive selected and belonging to Jordanian team of Diabetes (age: 21±0.7years, height: 164± 4 cm, mas:58± 0.2 kg, the experience of the disease, 13.3±0.8 years). The study sample was filmed by using video camera (Sony HDR-CX220E) reached speed (50) frame/s. The study results showed that musculoskeletal system for Diabetic Type I differences in their shape of musculoskeletal the rest of the population, consequently people with Type 1 Diabetes have a swayback posture and a lower chest forward posture. and the average of sample study in the flexion spine(77)° and (15)°for extension spine. Where it formed 81% from natural flexion spine and 45% from natural extension spine. The researchers recommend: the necessity informed Diabetic Type I on kinematic analysis of the musculoskeletal system.

851-P: Sleep and Quality of Life in Adolescents with Type 1 or Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 851-P
Author(s):  
MELISSA S. FAULKNER
Keyword(s):  
Quality Of Life ◽  
Type 2 Diabetes

Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality

2020 ◽  
Vol 17 (1) ◽  
pp. 37-54
Author(s):  
Tatyana Chalakova ◽  
Yoto Yotov ◽  
Kaloyan Tzotchev ◽  
Sonya Galcheva ◽  
Boyan Balev ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Diabetic Control ◽  
Macrovascular Complications ◽  
Morbidity And Mortality ◽  
Diabetes Mellitus Risk

: Type 1 diabetes mellitus (T1DM) is a chronic disease that starts early in life and often leads to micro- and macrovascular complications. The incidence of the disease is lower than that of type 2 DM and varies in different countries and ethnic groups, and the etiological and pathogenetic factors are different from T2DM. The aim of this overview is to investigate the effect of T1DM on all-cause mortality and CVD morbidity and mortality. During the last decades, the treatment of T1DM has improved the prognosis of the patients. Still, the mortality rates are higher than those of the age- and sex-matched general population. With the prolonged survival, the macrovascular complications and cardiovascular diseases (CVD) appear as major health problems in the management of patients with T1DM. The studies on the CVD morbidity and mortality in this disease group are sparse, but they reveal that T1DM is associated with at least 30% higher mortality. In comparison to healthy people, CVDs are more common in T1DM patients and they occur earlier in life. : Furthermore, they are a major cause for death and impaired quality of life in T1DM patients. The correlation between diabetic control and the duration of T1DM is not always present or is insignificant. Nevertheless, the early detection of the preclinical stages of the diseases and the risk factors for their development is important; similarly, the efforts to improve glycemic and metabolic control are of paramount importance.

Sign in / Sign up

Export Citation Format

Share Document